Scancell Investor Update Agenda

Published: Sep 24, 2013

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

September 24, 2013 -- Scancell Holdings Plc, (AIM:SCLP), the developer of novel immunotherapies for the treatment of cancer, is to host an Investor Update on Tuesday, 1 October 2013. Details of the event are:


FTI Consulting

Holborn Gate

26 Southampton Buildings

London, WC2A 1PB

10.45 Registration with refreshments

11.00 Introduction

David Evans, Scancell Non-Executive Chairman

11.05 Cancer immunotherapy

Prof Peter Stern, Head of the Immunology Group, Paterson Institute for Cancer Research, University of Manchester

11.20 Scancell corporate update

Dr Richard Goodfellow, Joint CEO of Scancell

11.30 SCIB1 trial update and introduction to Moditope™

Prof Lindy Durrant, Joint CEO of Scancell

11.45 Q&A

12.00 Interactive panel discussion

Led by Prof Karol Sikora, Dean of Medicine , University of Buckingham; Honorary Consultant Oncologist at Hammersmith Hospital

Panellists include:

Prof Lindy Durrant,

Prof Peter Stern,

Dr Steve Chan, Consultant Oncologist, City Hospital, Nottingham University

and Prof Christian Ottensmeier, Dept. of Experimental Medicine, University of Southampton

12.45 Buffet lunch

13.30 Close

For Further Information:

Dr Richard Goodfellow, Joint CEO

Professor Lindy Durrant, Joint CEO Scancell Holdings Plc

Scancell Holdings Plc + 44 (0) 20 7831 3113

Camilla Hume/Stephen Keys Cenkos Securities + 44 (0) 20 7397 8900

Mo Noonan/Eleanor Clarke FTI Consulting + 44 (0) 20 7831 3113

About Scancell

Scancell is developing novel immunotherapies for the treatment of cancer based on its ImmunoBody® and Moditope™ technology platforms. Scancell’s first ImmunoBody®, SCIB1 is being developed for the treatment of melanoma and is in Phase 1/2 clinical trials. Preliminary evidence from Part 1 of the study showing that SCIB1 produced an immune response which might be associated with clinical benefit in patients with malignant melanoma was released in December 2012.

Scancell’s ImmunoBody® vaccines target dendritic cells and stimulate both parts of the cellular immune system; the helper cell system where inflammation is stimulated at the tumour site; and the cytotoxic T-lymphocyte or CTL response where immune system cells are primed to recognise and kill specific cells.

Scancell has also identified and patented a series of modified epitopes that stimulate the production of killer CD4 that destroy tumours without toxicity. The Directors believe that the Moditope™ platform could play a major role in the development of safe and effective cancer immunotherapies in the future.

Eleanor Clarke

Team Assistant

Strategic Communications

F T I Consulting

+44(0) 203 077 0480 direct

Holborn Gate, 26 Southampton Buildings

London, WC2A 1PB

Help employers find you! Check out all the jobs and post your resume.

Back to news